HC Wainwright Has Positive Outlook for KYTX Q1 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Kyverna Therapeutics in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.62) for the quarter, up from their prior estimate of ($0.88). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.61) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting analysts’ consensus estimates of ($0.80).

KYTX has been the subject of a number of other research reports. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a report on Monday, December 15th. Wells Fargo & Company lifted their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Finally, Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Stock Up 1.6%

Shares of NASDAQ KYTX opened at $8.77 on Wednesday. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $13.67. The firm has a market cap of $384.13 million, a price-to-earnings ratio of -2.40 and a beta of 2.60. The company has a debt-to-equity ratio of 0.11, a quick ratio of 7.75 and a current ratio of 7.75. The stock’s 50-day simple moving average is $8.25 and its 200-day simple moving average is $7.70.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently bought and sold shares of KYTX. Price T Rowe Associates Inc. MD increased its holdings in Kyverna Therapeutics by 16.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock valued at $16,569,000 after buying an additional 250,418 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Kyverna Therapeutics during the 4th quarter worth approximately $15,667,000. AIGH Capital Management LLC acquired a new position in shares of Kyverna Therapeutics in the 4th quarter worth approximately $14,100,000. Vanguard Group Inc. grew its position in shares of Kyverna Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after acquiring an additional 9,858 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at approximately $9,220,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.